Teriparatide (Forteo): Uses, Dosing, Side Effects, and How It Compares to Bisphosphonates

What Is Teriparatide and How Does It Work?

Teriparatide is a recombinant form of the first 34 amino acids of human parathyroid hormone. Unlike bisphosphonates, which slow bone breakdown, teriparatide stimulates osteoblasts to form new bone. This makes it the first osteoanabolic therapy the FDA approved for osteoporosis, arriving on the market in November 2002 [1].

Mechanism of Action

Continuous exposure to parathyroid hormone accelerates bone resorption. Intermittent pulsed exposure, delivered through a single daily injection, has the opposite effect. The once-daily 20 mcg dose activates PTH1 receptors on osteoblast precursors, triggering the Wnt signaling pathway and increasing osteoblast survival [2]. Bone formation markers like P1NP rise within one month and peak by 6 to 12 months of therapy.

Why "Anabolic" Matters

Bisphosphonates reduce fracture risk by preserving existing bone architecture. Teriparatide adds new trabecular plates and increases cortical thickness, producing structural improvements that antiresorptive drugs cannot replicate [2]. This distinction is the reason guidelines position teriparatide for patients who need bone rebuilding, not just bone preservation.

Who Should Take Teriparatide?

The FDA label covers three populations: postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis at high fracture risk, and men or women with glucocorticoid-induced osteoporosis at high fracture risk [1]. "High fracture risk" typically means a T-score of -2.5 or lower with a prior fragility fracture, or a FRAX 10-year major osteoporotic fracture probability above 20%.

Guideline Positioning

The 2020 American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) guidelines recommend starting with an osteoanabolic agent (teriparatide or romosozumab) in patients classified as "very high fracture risk" rather than beginning with a bisphosphonate and escalating later [3]. The Endocrine Society's 2019 guideline echoes this approach, stating: "In postmenopausal women with osteoporosis at very high fracture risk, we suggest initial treatment with bone-forming therapy over antiresorptive therapy" [4].

Who Should Not Take It

Teriparatide carries FDA contraindications for patients with unexplained alkaline phosphatase elevation, Paget disease of bone, open epiphyses (children and adolescents), prior radiation therapy to the skeleton, pre-existing hypercalcemia, and bone metastases or active malignancies involving the skeleton [1]. The original label included a boxed warning about osteosarcoma based on rat studies using doses 3 to 58 times the human dose. The FDA removed this boxed warning in 2020 after post-marketing surveillance of over 1 million patient-years found no causal signal in humans [5].

The Key Trial: Fracture Prevention Data

The landmark Neer et al. (2001) trial randomized 1,637 postmenopausal women with prior vertebral fractures to teriparatide 20 mcg, teriparatide 40 mcg, or placebo for a median of 21 months [6]. Results for the 20 mcg group:

• Vertebral fractures: 65% relative risk reduction (5% vs. 14% placebo)
• Non-vertebral fragility fractures: 53% relative risk reduction (6% vs. 10% placebo)
• Lumbar spine BMD: 9.7% increase vs. 1.1% placebo
• Femoral neck BMD: 2.8% increase vs. -0.7% placebo

The 40 mcg dose offered marginal additional efficacy but more adverse events, which is why only the 20 mcg dose reached the market [6].

VERO Trial: Head-to-Head Against Risedronate

The VERO trial (N = 1,360) compared teriparatide 20 mcg daily to risedronate (Actonel) 35 mg weekly in postmenopausal women with severe osteoporosis over 24 months [7]. Teriparatide reduced new vertebral fractures by 56% relative to risedronate (5.4% vs. 12.0%; P <0.0001). Clinical fractures (a composite of clinical vertebral and non-vertebral fractures) were 52% lower with teriparatide (4.8% vs. 9.8%; P <0.001) [7]. This was the first trial to show superiority of an anabolic agent over an active bisphosphonate comparator in fracture outcomes.

How to Use Teriparatide: Dosing and Administration

The dose is fixed. Patients inject 20 mcg subcutaneously into the thigh or abdomen once daily using a prefilled multidose pen device. Each pen contains 28 days of doses. The pen must be stored refrigerated (2 to 8°C) and can be used for up to 28 days after the first injection [1].

Injection Technique Tips

Rotate injection sites daily. Administer at a consistent time, though the injection does not need to coincide with meals. After injection, patients should sit or lie down if they have a history of orthostatic hypotension. The first several doses commonly cause transient dizziness or palpitations that resolve within minutes.

The 24-Month Treatment Window

Cumulative use is capped at 24 months per the FDA label. After stopping teriparatide, BMD gains at the spine decline within 12 to 18 months unless an antiresorptive is started [8]. The standard transition protocol is to begin alendronate 70 mg weekly, zoledronic acid 5 mg IV annually, or denosumab 60 mg every 6 months immediately after the last teriparatide injection.

Side Effects and Safety Profile

Teriparatide has a well-characterized safety profile based on over two decades of post-marketing data.

Common Adverse Events

Nausea affects roughly 9% of patients in clinical trials (vs. 5% placebo). Dizziness occurs in approximately 8% of patients, headache in 8%, and leg cramps in 3% [1]. Transient hypercalcemia above the upper limit of normal occurs in about 11% of patients, typically peaking 4 to 6 hours post-injection and resolving within 16 hours. Clinically significant hypercalcemia requiring dose adjustment is uncommon [6].

Osteosarcoma Concern

Rats given teriparatide at high doses for nearly their entire lifespan developed osteosarcoma. The 15-year post-marketing surveillance study by Gilsenan et al. (2021), tracking over 1 million U.S. Patients, found no increase in osteosarcoma incidence compared to background population rates [5]. The FDA's 2020 decision to remove the boxed warning reflected this evidence.

Monitoring

Check serum calcium 1 month after starting. Repeat calcium and 25-hydroxyvitamin D annually. Serum P1NP (procollagen type I N-propeptide) at baseline and 3 months can confirm a bone formation response. A P1NP increase of 10 mcg/L or more from baseline generally indicates adequate osteoblast activation [4].

Cost, Insurance, and Access

Forteo's wholesale acquisition cost is approximately $3,900 per month. Most commercial insurers cover it after prior authorization, typically requiring documentation of a T-score at or below -2.5 plus at least one prior fragility fracture or bisphosphonate failure [9]. Medicare Part D plans generally cover Forteo under specialty tier with variable copays.

Biosimilar and Generic Field

The first teriparatide biosimilar in the U.S., from Pfenex/Alvogen, received FDA approval in 2023. Biosimilar pricing runs roughly 15 to 30% below brand Forteo, though formulary placement varies by insurer. A generic teriparatide from Teva also entered the market, widening access.

Reducing Out-of-Pocket Costs

Eli Lilly's Forteo Savings Card covers eligible commercially insured patients and can reduce copays to as little as $4 per month. Patients without insurance can apply through Lilly Cares, a patient assistance program providing Forteo at no cost to qualifying individuals earning below 300% of the federal poverty level [9].

Teriparatide vs. Bisphosphonates: A Direct Comparison

Bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) remain first-line for most patients with osteoporosis. Teriparatide fills a different role.

Mechanism Differences

Alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), and zoledronic acid (Reclast) all inhibit osteoclast-mediated bone resorption [10]. They preserve existing bone but do not build new bone architecture. Teriparatide stimulates osteoblasts to deposit new bone matrix, increasing trabecular connectivity and cortical thickness in ways bisphosphonates cannot achieve [2].

Efficacy Comparison

The DATA trial (N = 94) compared teriparatide alone, denosumab alone, and the combination in postmenopausal women. At 24 months, lumbar spine BMD increased 9.5% with teriparatide, 5.6% with denosumab, and 12.9% with both [11]. For bisphosphonate comparisons, the Fracture Prevention Trial showed alendronate 10 mg daily increased lumbar spine BMD by 8.8% at 3 years [12], while the HORIZON trial demonstrated zoledronic acid 5 mg IV annually increased lumbar spine BMD by 6.7% at 3 years and reduced hip fractures by 41% [13].

A rough hierarchy for spine BMD gains over the approved treatment duration:

| Agent | Spine BMD Gain | Fracture Reduction (Vertebral) | |---|---|---| | Teriparatide 20 mcg daily (21 mo) | ~9.7% | 65% vs. Placebo | | Zoledronic acid 5 mg IV yearly (36 mo) | ~6.7% | 70% vs. Placebo | | Alendronate 10 mg daily (36 mo) | ~8.8% | 44% vs. Placebo | | Risedronate 5 mg daily (36 mo) | ~5.4% | 41% vs. Placebo | | Ibandronate 2.5 mg daily (36 mo) | ~6.5% | 62% vs. Placebo (vertebral only) |

When to Choose Teriparatide Over a Bisphosphonate

Choose teriparatide for patients with T-scores at or below -3.0, those with multiple vertebral fractures, patients who fracture while on bisphosphonate therapy, and those with glucocorticoid-induced osteoporosis requiring rapid BMD recovery. Choose a bisphosphonate for patients with moderate fracture risk, those who cannot self-inject daily, or when cost and insurance barriers make teriparatide inaccessible.

Sequencing: What Comes Before and After Teriparatide

Treatment order matters. Starting with a bisphosphonate and switching to teriparatide blunts the anabolic response at the hip, though spine gains remain strong [14].

The "Anabolic First" Strategy

The AACE 2020 guidelines recommend beginning high-risk patients on an osteoanabolic agent first, then transitioning to a bisphosphonate or denosumab afterward [3]. Dr. Felicia Cosman, professor of medicine at Columbia University, has stated: "Giving the anabolic agent first and following with an antiresorptive consolidates and extends the gains. Reversing that sequence sacrifices hip-site benefit" [14].

Post-Teriparatide Transition Options

After completing 24 months of teriparatide, the three most commonly used transition agents are:

• Alendronate 70 mg weekly (oral, generic, cost-effective)
• Zoledronic acid 5 mg IV once yearly (best adherence profile)
• Denosumab 60 mg SC every 6 months (strongest BMD maintenance, but requires indefinite use or careful bisphosphonate bridging to prevent rebound vertebral fractures on discontinuation)

The DATA-Switch extension showed that switching from teriparatide to denosumab produced continued BMD gains through 48 months, reaching total spine BMD increases of approximately 18% from pre-treatment baseline [15].

Special Populations

Glucocorticoid-Induced Osteoporosis

The Saag et al. (2007) trial compared teriparatide to alendronate in 428 patients receiving long-term glucocorticoids (at least 5 mg prednisone equivalent daily for 3 or more months). At 18 months, teriparatide increased lumbar spine BMD by 7.2% vs. 3.4% for alendronate. New vertebral fractures occurred in 0.6% of the teriparatide group vs. 6.1% in the alendronate group (P = 0.004) [16]. This trial established teriparatide as the preferred agent for glucocorticoid-induced osteoporosis in high-risk patients.

Men with Osteoporosis

Teriparatide is FDA-approved for men with primary or hypogonadal osteoporosis at high fracture risk. The Orwoll et al. (2003) trial in 437 men with osteoporosis showed a 5.9% lumbar spine BMD increase at 11 months with teriparatide 20 mcg vs. 0.5% with placebo [17].

Renal Impairment

Teriparatide is not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to limited safety data and the risk of worsening hypercalcemia from impaired calcium excretion [1].

How Teriparatide Fits Into the Broader Treatment Field

Teriparatide was the only osteoanabolic option for 17 years until abaloparatide (Tymlos, approved 2017) and romosozumab (Evenity, approved 2019) expanded the category. Romosozumab, a sclerostin inhibitor, has a 12-month treatment window and produced larger 12-month spine BMD gains (13.3% in the FRAME trial) but carries a cardiovascular safety signal that limits its use in patients with recent MI or stroke [18].

For patients without cardiovascular contraindications, the choice between romosozumab and teriparatide often depends on insurance coverage, injection frequency preference (monthly vs. Daily), and treatment duration needs.